A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Alisertib (Primary) ; Sapanisertib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Solid tumours
- Focus Adverse reactions
- 05 Jun 2018 Results (n=5) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 16 May 2016 Status changed from not yet recruiting to recruiting.
- 29 Mar 2016 New trial record